| Filed On | Filing |
|---|---|
| 13 Nov 2026 | 10-Q |
| 13 Nov 2026 |
8-K: Results of Operations and Financial Condition
Advancing potential to execute Phase 3 development plan for fasedienol in social anxiety disorder following constructive FDA feedback, with disciplined capital management and strategic flexibility |
| 09 Nov 2026 |
8-K: Other Events
Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder |
| 30 Oct 2026 |
8-K: Costs Associated with Exit or Disposal Activities; Other Events
On October 26, 2026, Vistagen Therapeutics, Inc. (the “Company”) implemented a Board-approved reduction in workforce by approximately 31%, retaining core clinical, regulatory, technical, and corporate capabilities required for U.S. regis... |
| 09 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
1. Purpose. The Board of Directors of Vistagen Therapeutics, Inc. (the “Board”), a Nevada corporation (“Vistagen” or the “Company”), recognizes that a potential involuntary termination of employment of Vistagen’s senior management, inclu... |
| 25 Sep 2026 |
8-K: Regulation FD Disclosure
1 Nasdaq: VTGN Corporate Presentation Harnessing the therapeutic power and potential of brain regulation with nose-to-brain neurocircuitry September 2026 |
| 24 Sep 2026 |
8-K: Other Events
Exploratory research results presented at Psych Congress 2026 in New Orleans |
| 22 Sep 2026 |
8-K: Other Events
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder |
| 11 Sep 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On September 10, 2026, Vistagen Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). At the 2026 Annual Meeting, as set forth below, the Company’s stockholders: (i) elected each of ... |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | 10-Q |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition
Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies |
| 06 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose |
| 05 Aug 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On August 4, 2026, Vistagen Therapeutics, Inc. (the “Company”) received an extension notification (the “Extension Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“Nasdaq”) granting the Company a 180-day ex... |
| 31 Jul 2026 | DEFA14A |
| 31 Jul 2026 |
Proxy statement: annual meeting on September 10, 2026
CEO pay $1.2M, down 51% · say-on-pay vote |
| 31 Jul 2026 |
Form 4: Williamson Douglas J, Director
Granted 40,826 Stock Options (Right to Buy) |
| 31 Jul 2026 |
Form 3: Williamson Douglas J, Director
No securities owned |
Loading...